Protecting kidneys from damage caused by cisplatin chemotherapy
Save Kidneys in Cisplatin Chemotherapy by blocking HDAC6
This study is looking at whether blocking a certain protein can help protect your kidneys from damage caused by cisplatin, a chemotherapy drug used to treat cancer, and it aims to find ways to keep your kidneys healthier during treatment.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rhode Island Hospital NIH-funded |
| Lab location | 1 site (Providence, United States) |
| Project ID | NIH-10841270 on NIH RePORTER |
What this research studies
This research investigates how blocking a specific protein, histone deacetylase 6 (HDAC6), can help prevent kidney injury caused by cisplatin, a common chemotherapy drug used to treat solid tumors. The study aims to understand the mechanisms behind kidney damage during cisplatin treatment and explore the potential of HDAC6 inhibition as a protective strategy. By using animal models, researchers will assess how this approach can reduce kidney damage and improve overall kidney health in patients undergoing chemotherapy.
Who could benefit from this research
Good fit: Ideal candidates for this research are cancer patients who are receiving cisplatin chemotherapy and are at risk of kidney damage.
Not a fit: Patients who are not undergoing cisplatin treatment or those with pre-existing severe kidney disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that protect patients' kidneys during cisplatin chemotherapy, reducing the risk of kidney injury.
How similar studies have performed: Preliminary studies have shown promise in using HDAC6 inhibition to protect against kidney injury, suggesting that this approach may be effective.
Where this research is happening
Providence, United States
- Rhode Island Hospital — Providence, United States (Active)
Researchers
- Principal investigator: Zhuang, Shougang — Rhode Island Hospital
- Study coordinator: Zhuang, Shougang
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.